2016 American Society of Clinical Oncology Annual Meeting*

Download All
June 3-7, 2016; Chicago, Illinois
Review key presentations on immunotherapy from the 2016 American Society of Clinical Oncology Annual Meeting.
David R. Gandara, MD
Daniel M. Geynisman, MD
Sara Hurvitz, MD, FACP
Elias Jabbour, MD
Shaji K. Kumar, MD
Brian Rini, MD, FASCO
Tiffany A. Traina, MD
Heather Wakelee, MD

Immunotherapy

Phase Ib trial of combination therapy with atezolizumab and nab-paclitaxel showed a safety profile similar to each agent alone and produced durable responses in patients with mTNBC.

Released: June 7, 2016

Updated data in patients with mismatch repair–deficient metastatic CRC show potential association with treatment response to pembrolizumab.

Released: June 9, 2016

PD-L1 expression, TCGA subtype, and mutational load were independent predictors of atezolizumab response in patients with mUC, and response prediction improved significantly with combination of these markers.

Released: June 14, 2016

Evaluation of patients with metastatic NSCLC treated past first RECIST defined progression with anti–PD-1 therapy in clinical trials finds that a small proportion (8%) attained a subsequent response to treatment.

Released: June 6, 2016

Immunoscore found to be predictive of time to recurrence, disease-free survival, and OS in colon cancer.

Released: June 14, 2016

MEK and PD-L1 inhibitors show potential synergy in MSS and chemorefractory KRAS-mutant mCRC.

Released: June 10, 2016

Nivolumab treatment beyond progression associated with reduced tumor burden, improved OS, and lower incidence of all grade adverse events in patients with advanced RCC.

Released: June 9, 2016

Atezolizumab shows rapid and durable clinical responses and a tolerable safety profile in heavily pretreated patients with metastatic urothelial carcinoma.

Released: June 6, 2016

Phase Ib trial of pembrolizumab in PD-L1–positive advanced cervical cancer showed promising 6-month OS of 67% and safety profile similar to that seen in other tumor types.

Released: June 9, 2016

Fractionated dosing of CTL019 minimized CRS-related toxicity and maintained high response rates in patients with relapsed/refractory CD19+ ALL.

Released: June 6, 2016

Early-phase study of pembrolizumab plus lenalidomide plus dexamethasone in heavily pretreated MM showed 50% ORR, including a 38% rate in lenalidomide-refractory patients.

Released: June 8, 2016

Median OS not reached for pembrolizumab at median follow-up of 23 months, with continuing durable responses and favorable safety profile.

Released: June 13, 2016

Pembrolizumab plus ipilimumab appear to be well tolerated and produced robust, durable responses in patients with advanced melanoma.

Released: June 14, 2016

Small phase Ib trial demonstrated that combination treatment with T-VEC plus pembrolizumab in advanced unresectable melanoma yields ORR of 57% and CR of 24%.

Released: June 6, 2016

David R. Gandara, MD; Daniel M. Geynisman, MD; Sara Hurvitz, MD, FACP; Elias Jabbour, MD; Shaji Kumar, MD; Brian Rini, MD, FACP; Tiffany A. Traina, MD; and Heather A. Wakelee, MD, each provide an analysis of key presentations on cancer immunotherapy from the 2016 clinical oncology meeting in Chicago.

David R. Gandara, MD Daniel M. Geynisman, MD Sara Hurvitz, MD, FACP Elias Jabbour, MD Shaji K. Kumar, MD Brian Rini, MD, FASCO Tiffany A. Traina, MD Heather Wakelee, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: September 23, 2016 Expired: No longer available for credit

Atezolizumab shows rapid and durable clinical responses and a tolerable safety profile in previously untreated, cisplatin-ineligible patients with advanced or metastatic urothelial carcinoma.

Released: June 6, 2016

David R. Gandara, MD; Daniel M. Geynisman, MD; Sara Hurvitz, MD, FACP; Elias Jabbour, MD; Shaji Kumar, MD; Brian Rini, MD, FACP; Tiffany A. Traina, MD; and Heather A. Wakelee, MD, provide an analysis of key presentations on cancer immunotherapy from the 2016 Clinical Oncology meeting in Chicago.

Released: September 19, 2016
Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC in collaboration with Postgraduate Institute for Medicine
ACHS Logo

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

This activity is supported by educational grants from
Amgen
Ariad Pharmaceuticals
Bayer HealthCare Pharmaceuticals Inc.
Celgene Corporation
Genentech
Incyte
Merck & Co., Inc.
Taiho Pharmaceuticals

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue